Connection

Robert Price to Inflammatory Bowel Diseases

This is a "connection" page, showing publications Robert Price has written about Inflammatory Bowel Diseases.
Connection Strength

0.413
  1. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine. 2016 Jan; 77:44-9.
    View in: PubMed
    Score: 0.119
  2. The emerging role of leptin antagonist as potential therapeutic option for inflammatory bowel disease. Int Rev Immunol. 2014 Jan; 33(1):23-33.
    View in: PubMed
    Score: 0.101
  3. Alternative medicines as emerging therapies for inflammatory bowel diseases. Int Rev Immunol. 2012 Feb; 31(1):66-84.
    View in: PubMed
    Score: 0.092
  4. Genistein induces macrophage polarization and systemic cytokine to ameliorate experimental colitis. PLoS One. 2018; 13(7):e0199631.
    View in: PubMed
    Score: 0.036
  5. An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2018 08 01; 315(2):G220-G230.
    View in: PubMed
    Score: 0.035
  6. Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation. Brain Behav Immun. 2017 Jan; 59:10-20.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.